ClinicalTrials.gg
Status unknownNCT04658056Updated Dec 8, 2020

UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

An observational study in Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by PROCEPT BioRobotics. Status unknown at 1 site in United Kingdom. Open to male participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by PROCEPT BioRobotics · Observational

How we know

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
46
Ages
45 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Prostatic Hyperplasia with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Hyperplasia · United Kingdom.

Started
2021
with 1 other
Observational
6 of 26
1 open now
Registered
24th of 26
by date
Lead sponsor
2 of 26
PROCEPT BioRobotics

Among the 26 studies in Prostatic Hyperplasia with a site in United Kingdom, this one is one of 2 that started in 2021, is one of 6 observational ones, and was the 24th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies in Prostatic Hyperplasia with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years to 85 Years · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Prostatic Hyperplasia with a site in United Kingdom, or all of them as a file.
02

Study summary

A post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS).

Read the detailed description

The study is a post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS). In POST WATER, up to 46 WATER Study subjects in the United Kingdom who were active on the study at 36 months will be invited to participate, across 3 clinical study sites in England and Wales. The study will consist of one follow-up time-point at 60 months (5 years) from the time of initial WATER Study treatment date.

03

Conditions studied

  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptoms
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

The target patient population is subjects who were enrolled in the WATER Study (with symptomatic BPH) who were randomized to treatment with either the Aquablation procedure or TURP.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject was randomized and received treatment in the WATER Study.
  2. Subject is mentally capable and willing to sign a study-specific form
  3. Subject is willing and able to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

Dementia or psychiatric condition that prevents the participant from completing required follow up 2. Participating in another study that could affect responses to the study assessments

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
46 participants (estimated)
Patient registry
No

Groups and cohorts

  • WATER AQUABEAM Robotic System cohort

    WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.

  • WATER TURPS cohort

    WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.

06

What researchers measure

Primary outcomes

  1. Long-term effectiveness as measured by IPSS at 60 months

    International Prostate Symptom Score at 60 months as compared to baseline

    Time frame: 60 months following original surgical intervention

  2. Long-term safety as measured by adverse events at 60 months

    The proportion of subjects with adverse events classified as Clavien-Dindo Grade 2 or higher or any grade 1 event resulting in persistent disability

    Time frame: 60 months following original surgical intervention

Other outcomes

  1. Reoperation or Re-intervention at 60 months

    Reoperation or Re-intervention at 60 months

    Time frame: 60 months

  2. IPSS-QoL at 60 months

    International Prostate Symptom Score Quality of Life sub-score

    Time frame: 60 months

  3. Qmax at 60 months

    Uroflowmetry measurement of voided urine (in milliliters) per unit of time (in seconds)

    Time frame: 60 months

  4. PVR at 60 months

    Post-void residual urine test

    Time frame: 60 months

  5. Erectile function at 60 months

    IIEF-15 score

    Time frame: 60 months

  6. MSHQ-EjD at 60 months

    Assessment of ejaculatory function/dysfunction

    Time frame: 60 months

07

Study locations

1 site
  • Frimley Park Hospital
    Camberley, Surrey GU16 7UJ, United Kingdom
08

References and documents

Publications

  • Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079. PubMed 32065861 ↗
  • Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Adv Ther. 2019 Jun;36(6):1326-1336. doi: 10.1007/s12325-019-00952-3. Epub 2019 Apr 26. PubMed 31028614 ↗
  • Pimentel MA, Yassaie O, Gilling P. Urodynamic Outcomes After Aquablation. Urology. 2019 Apr;126:165-170. doi: 10.1016/j.urology.2019.01.020. Epub 2019 Feb 2. PubMed 30721737 ↗
  • Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Roehrborn C. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. Urology. 2019 Mar;125:169-173. doi: 10.1016/j.urology.2018.12.002. Epub 2018 Dec 12. PubMed 30552937 ↗
  • Chughtai B, Thomas D. Pooled Aquablation Results for American Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in Large Prostates (60-150 cc). Adv Ther. 2018 Jun;35(6):832-838. doi: 10.1007/s12325-018-0722-0. Epub 2018 Jun 5. PubMed 29873008 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2021; primary completion for Jan 2022, 12 months later.

Of 76 observational studies under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartEst.
Jan 2021
Primary completionEst.
Jan 2022
CompletionEst.
Feb 2022
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04658056
Lead sponsor
PROCEPT BioRobotics
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Jan 2021 (estimated)
Primary completion
Jan 2022 (estimated)
Completion
Feb 2022 (estimated)
Last update
Dec 8, 2020

Study contacts

Angela Lee
Contact
a.lee@procept-biorobotics.com
+46 738417897
Claus Roehrborn, MD
principal investigator · UT Southwestern Medical
Peter Gilling, MD
principal investigator · Tauranga Urology Research Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion